Population pharmacokinetics/pharmacodynamics relationships of an anticancer drug

Statistics in Medicine

Volumn 22, Issue 6, 2003, Pages 833-846

  Ané, Cécile ^a   Concordet, Didier ^a  

^a CNRS   (France)

Author keywords

Non linear mixed effects models; Pharmacodynamics; Pharmacokinetics; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; POPULATION RESEARCH; PREDICTION; STATISTICAL ANALYSIS; TOXICITY TESTING;

ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; FEMALE; HUMANS; LEUKOCYTE COUNT; MODELS, BIOLOGICAL; NEUTROPHILS; TOPOTECAN;

EID: 0037473225     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1448     Document Type: Article

References (11)

1. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donhower RC. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology 1992; 10:647-656.
2. Guichard S, Montazeri A, Chatelut E, Hennebelle I, Bugat R, Canal P. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation. Clinical Cancer Research 2001; 7:3222-3228.
3. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. Journal of Pharmacokinetics and Biopharmaceutics 1993; 21:457-478.
4. Gobburu JVS, Jusko WJ. Role of dosage regimen in controlling indirect pharmacodynamic responses. Advanced Drug Delivery Reviews 2001; 46:45-57.
5. Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K. Indirect-response model for the time course of leukopenia with anti-cancer drugs. Clinical Pharmacology and Therapeutics 1998; 64:511-521.
6. Zamboni WC, D'Argenio DZ, Stewart CF, MacVittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, Egorin MJ. Pharmacodynamic model of topotecan-induced time course of neutropenia. Clinical Cancer Research 2001; 7:2301-2308.
7. Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ. Models of schedule dependent haematological toxicity of 2′-deoxy-2′-methylidenecytinine (DMDC). European Journal of Clinical Pharmacology 2000; 56:567-574.
8. Friberg LE, Freijs A, Sandström M, Karlsson MO. Semiphysiological model for the time course of leukocytes after varying schedules of 5-Fluorouracil in rats. Journal of Pharmacology and Experimental Therapeutics 2000; 295(2):734-740.
9. Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Déporte-Féty R, Albin N, Laguerre B, Goupil A, Bugat R, Canal P, Chatelut E. Population pharmacokinetics of topotecan: Intraindividual variability of total drug. Cancer Chemotherapy and Pharmacology 2000; 46(5):375-381.
10. Beal SL, Sheiner LB. NONMEM user's guide. Nonlinear Mixed Effects Models for Repeated Measures Data. University of California: San Francisco, 1992.
11. O'Reilly S. Topotecan: what dose, what schedule, what route? Clinical Cancer Research 1999; 5:3-5.